4.5 Article

Impact of psoriatic arthritis and comorbidities on ustekinumab outcomes in psoriasis: a retrospective, observational BADBIR cohort study

相关参考文献

注意:仅列出部分参考文献,下载原文获取全部文献信息。
Review Pharmacology & Pharmacy

The Role of Real-World Evidence in FDA-Approved New Drug and Biologics License Applications

Christina A. Purpura et al.

Summary: During the period from January 2019 to June 2021, the US FDA approved 116 medical products, with 88 of them including RWE studies intended to provide evidence of safety or effectiveness. Among these studies, 65 influenced the FDA's final decision, and 38 were included in product labels. The approvals spanned 18 therapeutic areas and highlighted various quality issues related to RWE study. Future guidance on FDA's evidentiary expectations may emphasize the importance of real-world data selection and study design.

CLINICAL PHARMACOLOGY & THERAPEUTICS (2022)

Review Rheumatology

Comorbidities in psoriatic arthritis: a systematic review and meta-analysis

Sonal Gupta et al.

Summary: This systematic review and meta-analysis aimed to describe the prevalence of comorbidities in psoriatic arthritis (PsA), compare their incidence/prevalence between PsA and control populations, and examine their impact on PsA outcomes. The study found that comorbidities, especially cardiometabolic disorders, were highly prevalent in PsA patients and associated with adverse disease features. Further research is needed to understand the impact of comorbidities on long-term outcomes such as treatment response and mortality.

RHEUMATOLOGY INTERNATIONAL (2021)

Article Rheumatology

Real-World Treatment Persistence with Biologic Disease-Modifying Antirheumatic Drugs Among German Patients with Psoriatic Arthritis-A Retrospective Database Study

Philipp Sewerin et al.

Summary: This study investigated drug survival for bDMARDs in German PsA patients, finding an overall persistence rate of 57.5% with variations depending on the specific bDMARD used. Male patients had a significantly lower risk of treatment discontinuation.

RHEUMATOLOGY AND THERAPY (2021)

Review Medicine, General & Internal

Extra-Articular Manifestations and Comorbidities in Psoriatic Disease: A Journey Into the Immunologic Crosstalk

Lucia Novelli et al.

Summary: PsA is a chronic inflammatory disease affecting peripheral and axial joints, with possible presence of extra-articular manifestations and comorbidities. EAMs and comorbidities in PsA share common immunopathogenic pathways linked to systemic inflammation, and despite various therapies available, comprehensive disease control remains a challenge.

FRONTIERS IN MEDICINE (2021)

Article Dermatology

Modifiable risk factors and the development of psoriatic arthritis in people with psoriasis

A. Green et al.

BRITISH JOURNAL OF DERMATOLOGY (2020)

Review Rheumatology

Psoriatic arthritis and obesity: the role of anti-IL-12/IL-23 treatment

Luisa Costa et al.

CLINICAL RHEUMATOLOGY (2019)

Article Rheumatology

Psychosocial Factors and Central Sensitivity Syndromes

Leah M. Adams et al.

CURRENT RHEUMATOLOGY REVIEWS (2015)

Editorial Material Public, Environmental & Occupational Health

The Table 2 Fallacy: Presenting and Interpreting Confounder and Modifier Coefficients

Daniel Westreich et al.

AMERICAN JOURNAL OF EPIDEMIOLOGY (2013)

Review Rheumatology

Pain, catastrophizing, and depression in the rheumatic diseases

Robert R. Edwards et al.

NATURE REVIEWS RHEUMATOLOGY (2011)